Back to results
US 11,590,071 B2Granted
Injectable drug delivery implant composition and method of use thereof
AssigneeKing Abdulaziz University
InventorsImran Kazmi, Hemant Yadav, Fahad Fahad A. Al-Abbasi, Muhammad Shahid Nadeem, Hisham Altayeb, Muhammad Afzal, Gaurav Gupta, Abhay Raizaday
Life of this patent
Estimating the term…
Abstract
Provided are an injectable and implantable drug delivery composition and a method for using such composition to release active ingredients and/or pharmaceutical agents to a site of action. The composition includes a gellan-gum crosslinked with L-cysteine and at least one pharmaceutical active agent in a biocompatible solvent.
Claims10
An injectable drug delivery implant composition, comprising:
- a biodegradable water-soluble polymer, wherein the polymer is gellan gum crosslinked with L-cysteine, wherein the gellan gum crosslinked with L-cysteine is present at a concentration of 1-2% w/w based on the total weight of the composition;
- a biocompatible solvent;
- and
- a therapeutically effective amount of a biologically active agent, wherein the biologically active agent is dimethyl fumarate (DMF) or pharmaceutically acceptable salts thereof,
- wherein the gellan gum crosslinked with L-cysteine and the DMF or pharmaceutically acceptable salt thereof are at a weight ratio of about 0.5:1 to 3:1, and
- wherein the composition is in a liquid form and is configured to undergo gelation to form a gel-like implant in situ after injection into a subject.
3 more elements
A method of treating a subject suffering from multiple sclerosis (MS), comprising:
- parenterally injecting under the skin of the subject a composition comprising a biodegradable water-soluble polymer, wherein the polymer is gellan gum crosslinked with L-cysteine, wherein the gellan gum crosslinked with L-cysteine is present at a concentration of 1-2% w/w based on the total weight of the composition;
- a biocompatible solvent;
- and
- a therapeutically effective amount of a biologically active agent, wherein the biologically active agent is dimethyl fumarate (DMF) or pharmaceutically acceptable salts thereof,
- wherein the gellan gum crosslinked with L-cysteine and the DMF or pharmacologically acceptable salt thereof are at a weight ratio of about 0.5:1 to 3:1,
- wherein the biologically active agent is released from the gellan gum crosslinked with L-cysteine over time, pharmaceutically acceptable salt thereof and wherein the composition is parenterally injected once per week or less often.
3 more elements
Dependencies are inferred from the claim text.